Barrier Creams and Incontinence-Associated Dermatitis Prevention
Barrier creams are topical skin protectants applied to perineal and perigenital skin to prevent and treat incontinence-associated dermatitis (IAD) — the irritant contact dermatitis caused by prolonged exposure to urine and / or feces. They are a core component of structured incontinence skin-care and are explicitly endorsed by the AUA/SUFU 2024 OAB Guideline as part of the incontinence management strategies that should be discussed with all patients with urgency urinary incontinence.[1][2][3]
For the products that drive the chronic skin exposure barrier creams are protecting against, see Absorbent Products & the Pad Test. For external collection devices that can eliminate skin exposure entirely in refractory IAD, see Condom Catheters.
Definition and Concept
Barrier creams belong to the broader class of leave-on products — formulations of lipophilic ingredients (petrolatum, wax) and hydrophilic ingredients (water, glycerin) applied after cleansing. The protective effect is a coating action and creation of a hydrophobic film that reduces direct contact between urine / feces and the epidermis, reduces transepidermal water loss, and minimizes friction against absorbent products. Effects depend on the total formulation, not individual ingredients.[4][5]
Categories of Barrier Products
| Category | Key ingredients | Mechanism | Examples |
|---|---|---|---|
| Traditional creams / ointments | Zinc oxide, petrolatum, lanolin | Physical occlusive barrier; zinc oxide adds mild astringent / antimicrobial action | Sudocrem (15.25% zinc oxide), standard zinc oxide cream (32%), Desitin, A+D ointment[1] |
| Dimethicone (silicone) products | Dimethicone 1–3%, silicone polymers | Transparent water-insoluble protective film; breathable | Comfort Shield perineal washcloth (3% dimethicone); dimethicone silicone oil[1] |
| Film-forming polymers | Acrylate terpolymers; silicone-based sprays | Thin transparent film resistant to wash-off; does not interfere with pad adhesion | Cavilon No Sting Barrier Film; 3M skin protective film spray[1][2] |
| Cyanoacrylate-based protectants | 2-octyl cyanoacrylate (polymeric) | Polymerizes on skin into a durable transparent barrier; superior wash-off resistance; can be applied to denuded skin | Cavilon Advanced Skin Protectant[1][3][6] |
| Combination / multi-step bundles | Cleanser + moisturizer + protectant | Cleansing and barrier in one workflow | Comfort Shield (cleanser + moisturizer + dimethicone); Cavilon cleanser + barrier-cream bundles[1] |
Mechanism — How Barrier Creams Protect
IAD develops through a cascade:[1][2]
- Prolonged urine contact raises skin pH (normally ~5.5), activating fecal lipases and proteases that degrade the stratum corneum.
- Overhydration (maceration) further weakens the barrier.
- Friction from absorbent products compounds damage.
Barrier products counter this by:
- Hydrophobic layer reducing direct urine / fecal contact with epidermis
- Reducing transepidermal water loss and preventing maceration
- Minimizing friction between skin and absorbent product
- Mild antimicrobial / astringent action in some formulations (e.g., zinc oxide)[1][5]
Clinical Evidence
The 2025 Cochrane review (Graham et al.) is the contemporary evidence anchor — very low-certainty across all comparisons, with no single product demonstrating clear superiority.[4]
Leave-on vs leave-on (selected comparisons from Cochrane 2025)[4]
| Comparison | n | IAD rate | Effect |
|---|---|---|---|
| Petroleum jelly vs zinc oxide powder | 20 | 60% vs 40% | RR 1.50 (95% CI 0.60–3.74), NS |
| Sudocrem vs standard zinc oxide cream | 27 | 18.75% vs 18.18% | RR 1.03 (95% CI 0.20–5.19), NS |
| Dimethicone silicone oil vs acrylate terpolymer film spray | 56 | 17.9% vs 42.85% | RR 0.42 (95% CI 0.17–1.03), trend favoring dimethicone |
| 3M skin protective film vs IV3000 semipermeable film | 74 | 20.6% vs 47.5% | RR 0.43 (95% CI 0.21–0.90) — favors 3M film |
Bundle vs single product
- Adding Cavilon Advanced Skin Protectant to a cleansing routine: 13.3% vs 18.8% IAD (n = 31), trend not significant.[4]
- A structured protocol with zinc oxide after cleansing outperforms unstructured care without a protectant.[4]
- Stomahesive Protective Powder + film-forming product vs zinc oxide alone: 21.9% vs 83.9% IAD (RR 0.26, 95% CI 0.13–0.51) — large effect but very low certainty.[4]
Umbrella review
The 2023 nursing-practice umbrella review concluded that barrier films and lipophilic leave-on products are effective for preventing and treating IAD, but no single product is superior.[7]
Cyanoacrylate-Based Protectants — Emerging Category
Cyanoacrylate-based protectants (e.g., Cavilon Advanced Skin Protectant) polymerize on the skin to form a durable, transparent barrier. Comparative data:[5][6]
- 100% cyanoacrylate outperforms solvent-cyanoacrylate mixtures in ex-vivo porcine-skin urinary-incontinence simulations.
- Both maintain barrier protection over 8 days in clinical assessments.
- Particularly useful when applied to denuded or eroded skin, where traditional creams perform poorly.
Wash-Off Resistance
A healthy-volunteer head-to-head of five silicone-containing barrier creams found that Medi Derma-S, Cavilon Barrier Cream, and LBF Barrier Cream showed significantly superior moisture-barrier protection and wash-off resistance compared with Medihoney and Remedy Barrier Cream (p < 0.05).[8]
Guideline Position
| Source | Statement |
|---|---|
| AUA/SUFU 2024 OAB (Statement 10) | Discuss incontinence management strategies including barrier creams with all UUI patients (Expert Opinion); no head-to-head RCT data[3] |
| Wund-D.A.CH best-practice consensus | Continence management, efficient absorbent aids with good retention, consistent skin protection with barrier products, and adequate skin care are the effective strategies for IAD prevention[9] |
| General expert consensus | Three pillars of IAD prevention / treatment: (1) gentle cleansing; (2) hydrating topical agents; (3) barrier products. Recommendations remain largely expert-opinion-based[1] |
Structured Skin-Care Protocol
A practical regimen integrating evidence and consensus:[1][2][4]
- Cleanse. Gentle pH-balanced no-rinse or low-irritant cleanser after each incontinence episode. Avoid soap and water when possible — surfactants further damage the skin barrier.
- Moisturize. Apply a hydrating leave-on agent to maintain stratum-corneum hydration, particularly in elderly patients with xerotic skin.
- Protect. Apply a barrier product (cream, ointment, or film) to create a hydrophobic layer. Reapply after each cleansing for traditional creams; cyanoacrylate-based products may not require reapplication between episodes.
- Change absorbent products regularly. High-absorbency products with superabsorbent polymers reduce skin moisture exposure.
Treating Established IAD
| Severity | Management |
|---|---|
| Mild (erythema only) | Continue barrier product; consider switching to a more occlusive formulation[2] |
| Moderate (erosion / denudation) | Protect from further irritant exposure; cyanoacrylate-based protectants can be applied to damaged skin[6][10] |
| Severe | Short-term, controlled low-potency topical corticosteroid[10] |
| Secondary infection | Topical antifungals (candidiasis common) or topical antibiotics as indicated[10] |
| Refractory | External urine / stool collection devices or indwelling catheters to eliminate skin exposure entirely[2] |
Limitations of the Evidence
Across all comparisons, the evidence is very low certainty — small samples, heterogeneous interventions, and inconsistent endpoints. The 2025 Cochrane review concluded that some cleansers and leave-on products may be better than soap and water, and bundled approaches may outperform single products, but the results remain very uncertain and standardized multi-setting trials are needed.[4]
Key Principles
- Barrier creams prevent and treat IAD by creating a hydrophobic film; they are an essential component of incontinence skin care alongside gentle cleansing and absorbent-product hygiene.[1][2]
- AUA/SUFU 2024 recommends discussing barrier creams with all UUI patients as part of incontinence management.[3]
- No single product is superior across the evidence base; effectiveness depends on the total formulation rather than any single ingredient.[4][7]
- Cyanoacrylate-based protectants are durable, can be applied to denuded skin, and last multiple days — useful in moderate-to-severe IAD.[3][6]
- Wash-off resistance varies materially between brands — Medi Derma-S, Cavilon Barrier Cream, and LBF Barrier Cream outperform Medihoney and Remedy in head-to-head testing.[8]
- The structured protocol (cleanse → moisturize → protect → change absorbent product regularly) outperforms unstructured care.[4]
- Avoid soap and water; surfactants damage the skin barrier and worsen IAD.[1][2]
- For refractory IAD, eliminate skin exposure entirely with external collection devices or catheters rather than escalating topical therapy indefinitely.[2]
References
1. Beele H, Smet S, Van Damme N, Beeckman D. Incontinence-associated dermatitis: pathogenesis, contributing factors, prevention and management options. Drugs Aging. 2018;35(1):1-10. doi:10.1007/s40266-017-0507-1.
2. Kottner J, Dissemond J. Incontinence-associated dermatitis in older adults: a critical review of risk factors, prevention and management. Drugs Aging. 2025. doi:10.1007/s40266-025-01227-z.
3. Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985.
4. Graham T, Beeckman D, Kottner J, et al. Skin cleansers and leave-on product interventions for preventing incontinence-associated dermatitis in adults. Cochrane Database Syst Rev. 2025;7:CD011627. doi:10.1002/14651858.CD011627.pub3.
5. Woo K, Hill R, LeBlanc K, et al. Technological features of advanced skin protectants and an examination of the evidence base. J Wound Care. 2019;28(2):110-125. doi:10.12968/jowc.2019.28.2.110.
6. Pradhan MA, Nicholson LM, Coles LS, Campbell JJ, Curtis BJ. Comparative analyses of cyanoacrylates for barrier protection and incontinence-related wash-off resistance. Int Wound J. 2026;23(1):e70807. doi:10.1111/iwj.70807.
7. Fastner A, Hauss A, Kottner J. Skin assessments and interventions for maintaining skin integrity in nursing practice: an umbrella review. Int J Nurs Stud. 2023;143:104495. doi:10.1016/j.ijnurstu.2023.104495.
8. Dykes P, Bradbury S. Comparing the effectiveness and wash-off resistance of skin barrier creams: a healthy volunteer study. J Wound Care. 2017;26(9):552-557. doi:10.12968/jowc.2017.26.9.552.
9. Dissemond J, Assenheimer B, Gerber V, et al. Moisture-associated skin damage (MASD): a best practice recommendation from Wund-D.A.CH. J Dtsch Dermatol Ges. 2021;19(6):815-825. doi:10.1111/ddg.14388.
10. Sparling K, Frieden IJ, Butler DC. Incontinence-associated dermatitis: not just babies. J Am Acad Dermatol. 2025. doi:10.1016/j.jaad.2025.08.051.